Institut Merieux strengthens its international presence, particularly in Asia, with the creation of a base in China.
For 22 years Institut Merieux has been operating in China, where it will create a center combining R&D, bio-industrial and commercial activities. Following Europe and the United States, China will represent the third advanced base for Institut Merieux and its companies worldwide, in a region that has high-level potential in biology and substantial public health needs. Discussions are currently underway to finalize the necessary investments.
About Institut Merieux
With extensive experience in industrial microbiology, Institut Merieux contributes to serving medicine and public health across the globe. For the fight against infectious diseases and cancer, it imagines and develops new approaches in the fields of diagnostics, immunotherapy, and food safety and nutrition.
With its three business activities- bioMerieux, Transgene and Silliker-Institut Merieux has the potential to provide answers to the new challenges of public health globally: personalized medicine and new therapies, infectious diseases and cancer, food safety and nutrition.
bioMerieux, listed on the Euronext Paris market and 59% owned, is based in Marcy l'Etoile (France). World leader of in vitro diagnostics and industrial microbiological controls, bioMerieux employs 6,400 people. With a global presence in 150 countries, the group has a network of 39 subsidiaries and generates revenues amounting to 1,111 billion Euros.
Transgene: Based in Strasburg (France), this biotech company is 5
|SOURCE institut merieux|
Copyright©2009 PR Newswire.
All rights reserved